Bronchogen

Overview

Bronchogen is a short synthetic tetrapeptide belonging to the family of tissue-specific "peptide bioregulators" (sometimes called cytogens) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. Like other members of that family — for example Epitalon and Thymalin — it is promoted for a specific tissue, in this case bronchial / respiratory tissue.

The honest evidence picture is limited, older, and mostly Russian or preclinical. The only clearly verifiable peer-reviewed primary study located is an in-vitro biophysical study (Monaselidze, Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011) reporting that the peptide slightly raises the melting temperature of isolated DNA. That is a biophysical observation, not a demonstration of therapeutic efficacy. Broader claims about tissue repair, mucin/surfactant genes, or bronchial-epithelium effects appear largely in vendor and secondary material and could not be verified against primary peer-reviewed sources in this search — treat them as hypothesis.

There are no published human clinical trials in respiratory patients that could be located, and Bronchogen is not an approved medicine anywhere confirmed in the sources found. It is sold only as a research reagent.

Chemistry and structure

Bronchogen is described as a linear tetrapeptide built from four amino acids — alanine, glutamic acid, aspartic acid and leucine — but, as noted above, the order of those residues is reported inconsistently across primary sources.

The molecular formula (C18H30N4O9) and molecular weight (~446.45 g/mol) are consistent across the PubChem entries found. No CAS number could be located.

Mechanism of action

The mechanisms attributed to Bronchogen should be read cautiously: only the first is backed by a verifiable primary study, and it is a biophysical result rather than a therapeutic one.

• In vitro, Bronchogen raises the melting (denaturation) temperature of DNA by ~3.1°C. Using DNA from calf thymus and mouse liver, the effect appeared within a narrow peptide/DNA base-pair molar ratio (r ≈ 0.01–0.055) and was consistent with a DNA-stabilizing effect via non-specific binding to nitrogenous bases (no AT/GC preference). This is a biophysical observation, not evidence of clinical benefit. [In vitro] — Monaselidze, Khavinson et al., Bull Exp Biol Med 2011 (PMID 21240358)
• Proposed to act as a Khavinson "peptide bioregulator" that binds DNA/chromatin and modulates tissue-specific gene expression in bronchial/pulmonary tissue (e.g. epithelial differentiation, mucin or surfactant genes). Specific gene targets sometimes cited by vendors were not verified against a primary peer-reviewed source in this search. [Hypothesis] — vendor / secondary literature; specific gene-target claims unverified
• Reportedly synthesized on the basis of polypeptide fractions isolated from bronchial mucosa, and described as intended to stimulate reparative processes in bronchial cell cultures. This origin/repair claim was not confirmed against a primary source in this search. [Hypothesis] — vendor / secondary literature

Research and evidence

Human evidence. There are no well-established human clinical trials of Bronchogen. No published trials in respiratory disease could be located in searched primary databases (PubMed) as of 2026-07-08. Claims of respiratory or tissue benefit are preclinical or vendor-derived and are not supported by human data. Human pharmacokinetics, dosing, and safety data were not found.

Status and regulation

• Not approved by the FDA or EMA for any indication, and no evidence of a marketing authorization in any Western jurisdiction was found.
• Sold only as a research reagent ("for research use"). Any intended human use would make it an unauthorised (unlicensed) medicine.
• Whether Bronchogen holds any regulatory registration in Russia could not be verified in the sources found (no confirmed Russian registration located).
• WADA (anti-doping) status: not established. No authoritative WADA source could be found; vendor claims are contradictory and unsourced. A WADA class is not asserted here. WADA sport-eligibility is a separate axis from legality in any case.

Safety

• The human safety profile is uncharacterized: no human pharmacokinetic, dosing, or safety data were found. Absence of reported harms reflects absence of study, not a demonstration of safety.
• Material sold as "Bronchogen" is a research chemical; its identity, purity, and contaminant profile cannot be assumed to be controlled.
• As an injectable/reconstituted research peptide, the usual risks of non-sterile injectable products would apply in any unregulated use.

Legal status

Bronchogen is handled as a research reagent / research chemical ("for laboratory research use only"). That classification is not permission for human use: "no specific ban" is not affirmative authorisation, and the compound would become an unauthorised medicine the moment it is intended for human use. No jurisdiction is known, from the sources found, to have approved it as a medicine. Anti-doping status could not be authoritatively sourced and is treated as unknown. This is not legal advice — verify the rules in your own jurisdiction (dated 2026-07-08).

How it compares

Bronchogen is best understood alongside the other short Khavinson "peptide bioregulators", which share the same pattern of bold tissue-specific claims resting on a thin, mostly single-group, largely preclinical evidence base:

• Epitalon — a synthetic pineal-associated tetrapeptide (Ala-Glu-Asp-Gly) from the same school, promoted for longevity, with limited independent replication and very sparse human data.
• Thymalin — a thymus-derived peptide preparation from the same school, registered in Russia as an immunomodulator but not FDA/EMA-approved, with most evidence from one research group.

Compared with these, Bronchogen has an even thinner verifiable record: essentially one in-vitro biophysical paper, and no located human data at all.

Common misconceptions

• "Bronchogen is a proven lung/bronchial therapy." It is not. The only clearly verifiable primary finding is an in-vitro DNA-thermostability result; there are no located human trials.
• "The tissue-repair and gene-regulation mechanisms are established." Those claims are largely vendor-derived and were not verifiable against primary peer-reviewed sources; treat them as hypothesis, not fact.
• "The sequence is settled." Even the order of the four amino acids differs across primary sources (Ala-Asp-Glu-Leu vs Ala-Glu-Asp-Leu vs Glu-Asp-Leu-Ala).
• "Because it's unapproved, it must be WADA-banned (S0)." That inference is invalid. No authoritative WADA source was found; no class code is asserted here.
• "Research-use classification means it's legal to take." It does not. A research reagent becomes an unauthorised medicine the moment it is intended for human use.

Russian research

Much of the evidence for Bronchogen (the tetrapeptide AEDL, Ala-Glu-Asp-Leu) comes from Russian research — specifically the St. Petersburg Institute of Bioregulation and Gerontology / Pavlov Institute school associated with V.Kh. Khavinson. It is surfaced here for completeness and framed honestly: the located evidence is thin, mechanistic, and single-lineage. (Nomenclature note: the marketed peptide and PubChem entry [CID 471572] give the sequence as AEDL, Ala-Glu-Asp-Leu; the Khavinson primary studies cited below print the three-letter order as "Ala-Asp-Glu-Leu." The two refer to the same research peptide, but readers opening the primary sources will see the "Ala-Asp-Glu-Leu" rendering.)

• DNA thermostability [In vitro]. Monaselidze et al. reported that Bronchogen acted as a DNA-stabilizing agent, raising the DNA melting (denaturation) temperature of calf thymus and mouse liver DNA by ~3.1°C within a narrow peptide-to-base-pair molar ratio. This is a biophysical, calorimetric observation on isolated DNA only — no cellular or organismal endpoint. (Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, et al. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375–377. PMID 21240358; DOI 10.1007/s10517-011-1146-x.)

• Bronchial epithelium gene/protein expression [In vitro / human cells]. Khavinson et al. reported that the peptide (written "Ala-Asp-Glu-Leu / ADEL" in this paper) modulated proliferation/differentiation and apoptosis markers in cultured human bronchial epithelial cells (dissociated bronchoepithelial cells from human embryos, examined at the 1st, 7th and 14th passages). Reported changes included increased Ki67 (proliferation), Mcl-1 and NOS-3 (notably in older-passage cultures), regulation of p53 and CD79, and activation of the differentiation/secretory genes NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2, MUC4, MUC5AC and SFTPA1 (real-time PCR and immunocytochemistry). This is a cell-culture gene/protein-expression observation, NOT evidence of clinical benefit in patients. (Khavinson VKh, Tendler SM, Vanyushin BF, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781–791. PMID 25015171; DOI 10.1007/s00408-014-9620-7.)

• Same-group review [Review]. A Khavinson-group systematic review ("Peptide Regulation of Gene Expression: A Systematic Review") catalogues short Khavinson peptides and their proposed gene-expression roles, and secondary sources report it re-summarises the 2014 AEDL/bronchial findings. It is authored by the same group reviewing its own primary work, so it is NOT independent replication; the full-text AEDL passage could not be directly confirmed (publisher returned HTTP 403), and the AEDL bronchial content is therefore verified only via the 2014 primary study. (Khavinson VKh, Popovich IG, Linkova NS, et al. Molecules. 2021;26(22):7053. PMID 34834147; DOI 10.3390/molecules26227053.)

Several circulating claims could not be verified. A vendor "clinical study" (peptidebio.ru) asserting that patients taking Bronchogen had decreased sputum leukocytes/epithelial cells and improved bronchial patency, attributed to a Sept–Oct 2007 assessment at an "Institute of Bioregulation and Gerontology medical center," lists no author, journal, PMID, DOI, or eLIBRARY id — Russian-language sources describe this claim, but no independently verifiable citation was found, and it must NOT be presented as a clinical trial. Claims that Bronchogen is "bronchodilating," "anti-inflammatory," "regulates bronchial tone," "restores lung protective mechanisms," or "regenerates lung/bronchial tissue" appear only in Russian vendor/supplement marketing with no primary peer-reviewed citation located [Hypothesis]. A claim that it affects inflammatory pathways, epithelial cells and surfactant production specifically in RAT models is asserted by an English aggregator with no primary rat-model publication located — an unverified [Animal] claim that should not be asserted. No CAS number is assigned to Bronchogen (AEDL), and no authoritative WADA/anti-doping classification was located in any verifiable source.

On regulatory status: no confirmed Russian drug registration for injectable "Bronchogen" (the AEDL research peptide) was located. A related Khavinson respiratory bioregulator marketed to Russian consumers as an ORAL capsule is "Honluten" / "Chonluten" (Хонлутен, designation T-34) — but note that Honluten is a DIFFERENT peptide: the tripeptide Glu-Asp-Gly (EDG), not the oral form of Bronchogen/AEDL. It is sold as a peptide bioregulator / dietary supplement (БАД) "for prevention," NOT as a registered pharmaceutical, and is frequently paired with Bronchogen rather than being identical to it. Neither Bronchogen (AEDL) nor Honluten is FDA/EMA-approved for any indication, and both are sold internationally only "for research use." On quality: all located primary and review sources trace to Khavinson's St. Petersburg institute, so there is no independent replication; the studies are small, single-group, mechanism-level (two in-vitro results), with no reported statistical power, no dose-response in intact organisms, and no clinical endpoint, and there are no verifiable human clinical trials in respiratory patients. Being studied — or being sold in Russia as a bioregulator/supplement — is a regulatory and marketing fact, not proof of efficacy.